Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells $193,101.00 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 9,550 shares of the company’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $193,101.00. Following the completion of the transaction, the chief executive officer directly owned 462,577 shares of the company’s stock, valued at approximately $9,353,306.94. This represents a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Stock Performance

KALV stock opened at $19.56 on Thursday. The firm has a market cap of $1.00 billion, a PE ratio of -4.95 and a beta of -0.40. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. The business has a 50 day moving average of $17.67 and a 200-day moving average of $15.31. KalVista Pharmaceuticals, Inc. has a 12-month low of $9.83 and a 12-month high of $21.31.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its holdings in shares of KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of KalVista Pharmaceuticals in the third quarter worth $55,000. Wolverine Asset Management LLC bought a new position in shares of KalVista Pharmaceuticals in the third quarter worth $57,000. KLP Kapitalforvaltning AS bought a new position in shares of KalVista Pharmaceuticals in the third quarter worth $63,000. Finally, Truvestments Capital LLC boosted its holdings in shares of KalVista Pharmaceuticals by 253.8% in the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after acquiring an additional 3,360 shares during the period.

Analysts Set New Price Targets

Several equities analysts have weighed in on KALV shares. Needham & Company LLC increased their price objective on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Stifel Nicolaus increased their price objective on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Citizens Jmp reduced their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a report on Thursday, March 26th. Finally, Wall Street Zen lowered KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.60.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.